BRAF and non-small cell lung carcinoma: Considering Durvalumab outcomes by molecular subgroups, this study observed differences for Durvalumab as PFS among the different molecular subgroups in stage III unresectable NSCLC; patients with NSCLC with KRAS mutation had better ICI outcomes, in contrast to patients with other driver molecular alterations, such as EGFR mutations, BRAF mutations or ALK rearrangements.